Niemann-Pick C1 Like 1 (NPC1L1) is a protein localized in jejunal enterocytes that is critical for intestinal cholesterol absorption. The uptake of intestinal phytosterols and cholesterol into absorptive enterocytes in the intestine is not fully defined on a molecular level, and the role of NPC1L1 in maintaining whole body cholesterol homeostasis is not known. NPC1L1 null mice had substantially reduced intestinal uptake of cholesterol and sitosterol, with dramatically reduced plasma phytosterol levels. The NPC1L1 null mice were completely resistant to diet-induced hypercholesterolemia, with plasma lipoprotein and hepatic cholesterol profiles similar to those of wild type mice treated with the cholesterol absorption inhibitor ezetimibe. Cholesterol/cholate feeding resulted in down-regulation of intestinal NPC1L1 mRNA expression in wild type mice. NPC1L1 deficiency resulted in up-regulation of intestinal hydroxymethylglutaryl-CoA synthase mRNA and an increase in intestinal cholesterol synthesis, down-regulation of ABCA1 mRNA, and no change in ABCG5 and ABCG8 mRNA expression. NPC1L1 is required for intestinal uptake of both cholesterol and phytosterols and plays a major role in cholesterol homeostasis. Thus, NPC1L1 may be a useful drug target for the treatment of hypercholesterolemia and sitosterolemia.
Cholesterol absorption of both dietary cholesterol and cholesterol cleared from the liver through biliary secretion contributes along with regulation of cholesterol biosynthesis to maintain a tight control of cholesterol homeostasis. The mechanism by which cholesterol moves from the intestinal lumen into the absorptive enterocytes lining the proximal small intestine is poorly understood. The identification of ezetimibe as a potent selective inhibitor of intestinal cholesterol uptake and absorption confirmed this mechanism as a key point of therapeutic intervention for lowering plasma cholesterol levels and indicated that this process is mediated by a specific transporter (1) (2) (3) (4) . Based on the properties of ezetimibe in animal models of cholesterol uptake, it was predicted that such a transporter would be expressed in jejunal enterocytes and localized to the brush border membrane, which forms the interface between the intestinal lumen and the intracellular compartments responsible for cholesterol esterification and packaging into chylomicrons.
Through studies designed to understand the mechanism by which ezetimibe inhibits cholesterol absorption, we recently identified Niemann-Pick C1 Like 1 (NPC1L1) 1 as a critical protein for the intestinal absorption of dietary and biliary cholesterol (5) . NPC1L1 was identified through a genomics-bioinformatics approach by sequencing an expression sequence tags library from rat jejunum, annotating the sequences, and searching databases for intestinal proteins with features of a cholesterol transporter (5) . NPC1L1 was found to be highly expressed in the jejunum and localized on the surface of the absorptive enterocytes. Mice deficient in NPC1L1 exhibited a significant reduction in cholesterol absorption, and the low level of residual cholesterol absorption was insensitive to ezetimibe treatment. These previous results suggested that NPC1L1 resides in an ezetimibe-sensitive pathway responsible for cholesterol absorption (5) .
In addition to inhibiting cholesterol absorption, ezetimibe reduces plasma phytosterol levels in patients with hypercholesterolemia, although a molecular mechanism for intestinal phytosterol uptake and absorption has yet to be established (4) . Ezetimibe also effectively reduces phytosterol levels in patients with sitosterolemia, which is caused by a mutation in the ATP binding cassette (ABC) co-transporters, either ABCG5 or ABCG8 (7) . ABCG5 and ABCG8 are expressed on the apical surface of hepatocytes and enterocytes, and their function is required to export phytosterols into the bile and intestinal lumen, respectively. The present study describes the role of NPC1L1 in the selective intestinal uptake and absorption of cholesterol and phytosterols, regulation of the expression of intestinal NPC1L1, and other proteins related to sterol metabolism and resistance to diet-induced hypercholesterolemia in NPC1L1-deficient mice.
EXPERIMENTAL PROCEDURES
Materials-All solvents, chemicals, and sterols were purchased from Sigma-Aldrich Co. Campesterol was purchased from Supelco (Bellefonte, PA). Platinum quantitative PCR SuperMix-UDG (catalog no. 11730-017) was purchased from Invitrogen. [ 14 C]tri-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Animals-All animals were housed, treated, and cared for according to National Institutes of Health guidelines for the humane treatment of laboratory animals and the Animal Welfare Act in a program accredited by the American Association for Accreditation of Laboratory Animal Care under a protocol approved by the Schering-Plough Research Institute Animal Care and Use Committee. NPC1L1 null (Ϫ/Ϫ) mice were generated as previously described (5), with a targeting vector containing a LacZ-Neo-encoding cassette. Cellular localization of the LacZ in the mice was determined in 10-m tissue sections post-fixed in 0.5% glutaraldehyde and stained for ␤-galactosidase activity using a BetaGal staining kit (Invitrogen, catalog no. K1465-01). The colony of NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice was maintained at ScheringPlough Research Institute.
Cholesterol, Sitosterol, and Triglyceride Absorption-Cholesterol absorption was determined in NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice, and sitosterol and triglyceride absorption was determined in NPC1L1 (Ϫ/Ϫ) and (ϩ/ϩ) mice (3, 6) . Littermate or age-matched mice were fed a standard chow diet and gavaged with [
14 C]cholesterol, 1 Ci with 0.1 mg of unlabeled cholesterol (n ϭ 5-10/group), 2 Ci of [ 3 H]sitosterol (n ϭ 5/group), or 1 Ci of [carboxy- 14 C]triolein (n ϭ 4 -5/group) in 0.1 ml of corn oil. Two (cholesterol and triglyceride) or four (sitosterol) h later, plasma, livers, and small intestines were analyzed by liquid scintillation counting as previously described (6) . Sitosterol absorption (4 h) was also determined in female C57BL/6 mice treated orally with 10 mg/kg ezetimibe or corn oil vehicle 30 min before 2 Ci of [ 3 H]sitosterol administration (n ϭ 5/group).
Plasma Cholesterol, Sitosterol, and Campesterol Levels-Plasma sterol levels were determined in male littermate or age-matched NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice fed a standard chow diet. Plasma samples were analyzed by gas chromatography and mass spectrometry (GC-MS). Samples of plasma, 50 l each, were added to glass tubes containing 50 g epicoprostanol and 1 g stigmastanol solubilized in 10 l of toluene. Ethanolic potassium hydroxide (1 ml) was added to each sample, mixed, and incubated at 60°C for 1 h with shaking. The ethanolic KOH was prepared by diluting 6 ml of a 500 g/l aqueous solution of KOH to 100 ml with ethanol. After saponification, 1 ml water was added, and neutral sterols were extracted with 2 ml petroleum ether. The upper phase (1.6 ml) was collected and dried under a gentle stream of argon, and the remainder was redissolved in 100 l of a 1:2:3 mixture by volume of chlorotrimethylsilane, hexamethyldisilazane, and pyridine. The samples were incubated for 1 h at 60°C to convert free hydroxyl groups into trimethylsilyl ethers, dried under a stream of argon, dissolved in 500 l of isooctane, and divided in 2 aliquots which were analyzed by GC and GC-MS for determination of cholesterol and plant sterols, respectively.
For cholesterol, GC analysis was performed using an Agilent 6890 Plus instrument equipped with a split/splitless injector and a flame ionization detector using a 30-m, 0.32-mm inner diameter, 0.25-m-film HP-5 column. The oven temperature was kept at 280°C isothermally, and the split ratio was set to 1:20. 1 l of each sample was injected, and the amount of cholesterol was calculated from the ratio of the area of the cholesterol peak (retention time 6.46 min) to the area of the peak of the internal standard, epicoprostanol (retention time 5.50 min), using a standard curve. For campesterol and sitosterol, GC-MS analysis was performed using an Agilent 6890N instrument equipped with a split/splitless injector operating in the splitless mode coupled to an Agilent 5973 mass selective detector. A 30-m, 0.25-mm inner diameter, 0.25-m-film HP-5MS column was used. The injector temperature was set at 280°C, and oven temperature was programmed as follows: hold at 60°C for 2 min, 20°C/min to 180°C, 10°C/min to 250°C, 5°C/min to 300°C, hold at 300°C for 10 min. The transfer line was set at 300°C, and the mass spectrometer was operated in the electron ionization mode with the electron energy set at 70 eV. Selective ion monitoring for m/z 472, 486, and 488 was performed for the detection of campesterol (retention time 25.57 min), sitosterol (retention time 26.68 min), and stigmastanol (retention time 26.84 min), respectively. Each sample (1 l) was injected, and the amounts of campesterol and sitosterol were calculated from the ratio of the area of their respective peaks to the area of the peak of the internal standard, stigmastanol, using a standard curve.
Intestinal Cholesterol Synthesis-Cholesterol synthesis was determined in littermate or age-matched NPC1L1 (Ϫ/Ϫ) and (ϩ/ϩ) female mice fed a standard chow diet. Mice were orally gavaged with 2 Ci of [ 14 C]mevalonic acid in saline. One hour later proximal small intestine samples were collected (proximal half 2 cm distal to pylorus), lipids were extracted, and free cholesterol fractions were separated by thin layer chromatography (TLC) as previously described (8) . Analysis of TLC plate radioactivity was accomplished by phosphorimaging, digitizing, and computer quantitation (Storm 860 PhosphorImager Scanner and Image Quant Version 2.2, Molecular Dynamics, Piscataway, NJ).
Cholesterol-fed NPC1L1 Knockout Mice-Male littermate or agematched NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice (n ϭ 5/group) were fed rodent chow supplemented with 1% cholesterol and 0.5% sodium cholate for 7 days (Research Diets Inc., New Brunswick, NJ). Plasma lipoprotein profiles were determined by fast protein liquid chromatography with an Amersham Biosciences Superose 6 column. Fast protein liquid chromatography fractions, total plasma cholesterol, and bile cholesterol levels were determined using the Wako Cholesterol CII enzymatic colorimetric method (Wako Chemicals USA, Inc., Richmond, VA). Liver cholesterol levels were determined by high performance liquid chromatography essentially as described (9) .
Real-time Quantitative PCR Analysis-Real-time quantitative PCR analysis was performed as previously described (5) . The proximal half of the small intestine was collected from 2 cm distal to the pylorus and rapidly rinsed with sterile phosphate-buffered saline, and RNA was isolated as described (5) . Analysis was performed using Platinum Quantitative PCR SuperMix -UDG (Invitrogen) on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA). Tissue expression levels of individual genes were quantified and normalized against a control reaction for mouse 18 S RNA. Two independent reverse transcriptase reactions were each analyzed twice. Each analysis performed in triplicate included both 18 S RNA and the gene of interest primer/probe pairs as multiplexed reactions that contained 18 S primers at 200 nM each, 6-carboxyfluorescein (6FAM TM )/carboxytetramethylrhodamine (TAMRA TM )-labeled probe at 100 nM, gene-specific primers at 100 nM each, and VIC TM /carboxytetramethylrhodamine (TAMRA TM )-labeled probe at 50 nM. Primer probes used for PCR analysis are listed in Table I .
Statistical Analysis-Results are presented as the means Ϯ S.E of the mean. Statistical significance among groups was assessed using one way analysis of variance, Dunnett multiple comparisons test, and unpaired Student's t tests. p values less than 0.05 were considered significant.
RESULTS
NPC1L1 null (Ϫ/Ϫ) mice were generated by using a NPC1L1-targeting vector consisting of a LacZ-Neo-encoding cassette flanked by ϳ1.9 kilobases of 5Ј and 3.2 kilobases of 3Ј mouse genomic DNA sequence, resulting in the deletion from base 790 to 998 of the mouse NPC1L1 sequence (Deltagen Inc., Palo Alto, CA) (5). 129/OlaHsd ES cells injected into C57BL/6 blastocysts were used to generate chimeric mice. A colony of NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice was established initially by intercrossing 
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F1 heterozygous males and females. Tissue and cellular localization of the LacZ-Neo cassette in the NPC1L1 (Ϫ/Ϫ) mice was determined with a histochemical reaction for ␤-galactosidase activity. Extensive histological evaluations of tissues from the NPC1L1 (Ϫ/Ϫ) mice revealed that the LacZ-Neo cassette was highly expressed in the small intestinal enterocytes, primarily in the jejunum (Fig. 1 ). No other tissue or cellular expression was found in the (Ϫ/Ϫ) mice, except for intestinal enterocytes over Peyer's patches and a few isolated cells at the base of the stomach mucosa. The tissue distribution of NPC1L1 expression demonstrated by the LacZ-Neo cassette supports the participation of NPC1L1 in cholesterol absorption, which occurs primarily in the proximal jejunum. Cholesterol absorption into plasma and liver and intestinal cholesterol uptake was determined in the NPC1L1 null (Ϫ/Ϫ), heterozygous (ϩ/Ϫ), and wild type (ϩ/ϩ) mice at 2 h after administration of [ 14 C]cholesterol (Fig. 2, A and B) . The (Ϫ/Ϫ) mice absorbed 86 and 79% less cholesterol into the plasma and liver compared with (ϩ/ϩ) and the (ϩ/Ϫ) mice, respectively (p Ͻ 0.05). Cholesterol absorption in the (ϩ/Ϫ) mice appeared to be reduced compared with the (ϩ/ϩ) mice, but the difference was not statistically significant ( Fig. 2A) . Cholesterol uptake by the proximal small intestine was reduced by 64% in the (Ϫ/Ϫ) mice compared with the (ϩ/ϩ) mice (Fig. 2B ) (p Ͻ 0.01). These results are consistent with the previous observation that cholesterol absorption is severely reduced in NPC1L1 (Ϫ/Ϫ) mice when measured by the fecal dual-isotope method (5) and strongly support the role of NPC1L1 as a critical component of the cholesterol absorption pathway.
Sitosterol absorption and intestinal uptake was determined 4 h after administering [ 3 H]sitosterol to NPC1L1 (Ϫ/Ϫ) and (ϩ/ϩ) mice (Fig. 2, A and B) . Sitosterol absorption was significantly reduced in the (Ϫ/Ϫ) mice by 64% compared with (ϩ/ϩ) mice. The uptake of sitosterol into the intestine was also reduced by 52% in the (Ϫ/Ϫ) mice compared with the (ϩ/ϩ) mice (Fig. 2B ) (p Ͻ 0.01). A single 10-mg dose of ezetimibe was found to reduce sitosterol absorption by 67% from 0.356 Ϯ 0.043 to 0.116 Ϯ 0.011% of the administered labeled sitosterol in wild type C57BL/6 mice (p Ͻ 0.001). Intestinal sitosterol uptake was reduced by 55% in ezetimibe-treated mice, from 3.04 Ϯ 0.29 to 1.36 Ϯ 0.14% (p Ͻ 0.001). Thus, the degree of reduction for sitosterol absorption and intestinal uptake in the NPC1L1 (Ϫ/Ϫ) mice was very similar to that observed in wild type mice treated with ezetimibe.
Because ezetimibe specifically inhibits sterol absorption without affecting absorption of triglycerides (3), triglyceride absorption and intestinal uptake was evaluated in the NPC1L1 (Ϫ/Ϫ) compared with wild type mice (ϩ/ϩ). Intestinal triglyceride uptake and absorption into the liver and plasma compartments was not altered in the (Ϫ/Ϫ) mice relative to the (ϩ/ϩ) mice (Fig. 2, A and B) .
Plasma cholesterol and phytosterol levels were measured in chow-fed NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice (Fig. 3) to determine whether deletion of NPC1L1 reduced basal levels of phytosterols, as would be predicted from its apparent role in phytosterol absorption. Plasma cholesterol levels were similar among the (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice. The plasma levels of the phytosterols, sitosterol and campesterol, were extremely low in the (Ϫ/Ϫ) mice and were reduced by greater than 90% relative to the (ϩ/ϩ) mice and from 83-92% relative to the (ϩ/Ϫ) mice (p Ͻ 0.01). The phytosterol levels in the NPC1L1 (5), with a targeting vector containing a LacZ-Neo-encoding cassette. Cellular localization of the LacZ in the mice was determined in 10-m tissue sections post-fixed in 0.5% glutaraldehyde and stained for ␤-galactosidase activity. Extensive histological tissue evaluations revealed that the LacZ-Neo cassette was highly expressed in the small intestinal enterocytes, primarily in the jejunum (blue staining). Bright field micrograph of jejunum cryosection analyzed by ␤-galactosidase histochemistry counterstained with eosin (bar, 100 m).
heterozygous (ϩ/Ϫ) mice were reduced compared with the (ϩ/ϩ) mice by 37 and 50% for sitosterol and campesterol, respectively (p Ͻ 0.05). These results support the hypothesis that NPC1L1 is part of the major pathway by which phytosterols are absorbed.
The effect of cholesterol feeding on plasma cholesterol and lipoprotein cholesterol profiles was determined in the null (Ϫ/Ϫ), heterozygous (ϩ/Ϫ), and wild type (ϩ/ϩ) mice. The mice were fed a diet containing 1% cholesterol and 0.5% sodium cholate for 7 days, and a group of (ϩ/ϩ) mice was also treated with the cholesterol absorption inhibitor ezetimibe at 10 mg/ kg/day. Plasma cholesterol levels increased 2-fold in the (ϩ/ϩ) mice, whereas plasma cholesterol levels did not significantly change in the (ϩ/Ϫ) or the (Ϫ/Ϫ) mice (Fig. 4A) . Ezetimibe treatment of the (ϩ/ϩ) mice inhibited the rise in plasma cholesterol levels and resulted in plasma cholesterol levels similar to the (ϩ/Ϫ) and (Ϫ/Ϫ) mice. Plasma lipoprotein profiles of the mice revealed that cholesterol feeding did not alter the lipoprotein-cholesterol profiles in the (ϩ/Ϫ) and (Ϫ/Ϫ) mice relative to non-cholesterol-fed mice (Fig. 5) . The lipoprotein-cholesterol levels in the (ϩ/ϩ) mice were found to increase primarily in the VLDL and LDL fractions ( Fig. 5 and 6) . Compared with the cholesterol-fed (ϩ/ϩ) mice, the VLDL cholesterol levels were significantly reduced in the (ϩ/Ϫ) and (Ϫ/Ϫ) mice as well as in the ezetimibe-treated (ϩ/ϩ) mice (Fig. 6) (p Ͻ 0.05) . LDL cholesterol levels were also significantly lower in the (Ϫ/Ϫ) mice compared with the cholesterol-fed (ϩ/ϩ) mice (Fig. 6) . The plasma lipoprotein profile of the cholesterol-fed, ezetimibetreated (ϩ/ϩ) mice was similar to that of the cholesterol-fed (Ϫ/Ϫ) mice. Thus, the absence of NPC1L1 prevents the elevation in VLDL and LDL cholesterol observed upon increasing dietary cholesterol.
Hepatic cholesterol levels increase in rodents fed cholesterolcontaining diets. The appearance of the livers from wild type (ϩ/ϩ) mice and NPC1L1 null (Ϫ/Ϫ) mice fed the cholesterolcontaining diet for 7 days were dramatically different. The livers from the (ϩ/ϩ) mice were pale from the accumulation of lipids, whereas the livers from the (Ϫ/Ϫ) mice appeared like normal livers from chow-fed mice. Hepatic cholesteryl ester levels were determined in the mice (Fig. 4B ) and confirmed the qualitative visual observation. Feeding a diet containing 1% cholesterol and 0.5% sodium cholate for 7 days to (ϩ/ϩ) mice caused a 7-fold increase in hepatic cholesteryl ester content compared with chow-fed (ϩ/ϩ) animals (p Ͻ 0.001). Among the chow-fed groups, the (ϩ/Ϫ) mice showed no decrease in hepatic cholesteryl ester content, whereas there was a small but significant decrease in the (Ϫ/Ϫ) mice compared with the (ϩ/ϩ) mice (Fig. 4B) . With cholesterol feeding, hepatic cholesteryl ester levels increased 2-fold in the NPC1L1 heterozygous (ϩ/Ϫ) mice compared with chow-fed (ϩ/Ϫ) mice (p Ͻ 0.05). However, hepatic cholesterol levels remained 79% lower in the (ϩ/Ϫ) mice than the levels observed in the cholesterol-fed (ϩ/ϩ) mice (p Ͻ 0.01). The NPC1L1 null (Ϫ/Ϫ) mouse hepatic cholesteryl ester levels increased slightly with cholesterol feeding but remained 86% lower than those of the cholesterol-fed (ϩ/ϩ) mice (p Ͻ 0.01). Ezetimibe treatment of cholesterol-fed (ϩ/ϩ) mice prevented accumulation of cholesterol in the liver, and final levels of cholesteryl esters were the same as those for the cholesterol-fed NPC1L1 (Ϫ/Ϫ) mice (Fig. 4B) . The deletion of NPC1L1 matched the effect of ezetimibe treatment on hepatic cholesterol content under conditions of cholesterol feeding in mice.
Levels of cholesterol in gall bladder bile were also evaluated in the groups of cholesterol-fed mice. The biliary cholesterol concentrations were 11.1 Ϯ 1.01 mol/ml in the (ϩ/ϩ) group, 7.36 Ϯ 0.58 mol/ml in the (ϩ/Ϫ) group, 7.37 Ϯ 1.00 mol/ml in the (Ϫ/Ϫ) group, and 6.15 Ϯ 0.55 mol/ml in the (ϩ/ϩ) mice treated with ezetimibe. The biliary cholesterol levels were significantly less in the NPC1L1 (ϩ/Ϫ), (Ϫ/Ϫ), and the ezetimibetreated (ϩ/ϩ) mice compared with the cholesterol-fed wild type mice (p Ͻ 0.05), suggesting a decrease in the hepatic cholesterol pool with a deletion or reduction in NPC1L1 expression or ezetimibe treatment.
Because cellular cholesterol metabolism is under tight control and NPC1L1 deficiency may alter the size of the intracel -FIG. 3 . Plasma cholesterol, sitosterol, and campesterol levels in NPC1L1 knockout mice. NPC1L1 null (Ϫ/Ϫ) (black bars), heterozygous (ϩ/Ϫ) (hatched bars), and wild type (ϩ/ϩ) (white bars) mice fed rodent chow were evaluated for plasma cholesterol, sitosterol, and campesterol levels by gas chromatography and mass spectrometry. Values are mean Ϯ S.E., with n ϭ 4 -5/group; **, p Ͻ 0.01 compared with wild type mice (ϩ/ϩ) and heterozygous (ϩ/Ϫ) mice; *, p Ͻ 0.05 compared with (ϩ/ϩ) mice.
FIG. 4. Plasma and hepatic cholesterol levels in cholesterolfed NPC1L1 knockout mice. NPC1L1 null (Ϫ/Ϫ) (black bars), heterozygous (ϩ/Ϫ) (hatched bars)
, and wild type (ϩ/ϩ) (white bars) mice were fed a basal rodent chow or chow containing 1% cholesterol and 0.5% sodium cholate for 7 days. A group of cholesterol-fed (ϩ/ϩ) mice were treated with ezetimibe (EZE, 10 mg/kg/day) for 7 days (striped bars). Mice were evaluated for plasma total cholesterol (A) and hepatic cholesteryl ester (B) levels. Values are mean Ϯ S.E., with n ϭ 4 -5/ group; *, p Ͻ 0.001 compared with all other groups; **, p Ͻ 0.05 compared with same genotype chow-fed group; ***, p Ͻ 0.05 compared with chow-fed wild type mice (ϩ/ϩ) mice. lular regulatory cholesterol pool, alterations in the intestinal mRNA expression of proteins involved in sterol metabolism were determined in the chow-and cholesterol-fed NPC1L1 null (Ϫ/Ϫ), heterozygous (ϩ/Ϫ), and wild type (ϩ/ϩ) mice. NPC1L1 mRNA was absent in the proximal (jejunum) small intestine of the NPC1L1 (Ϫ/Ϫ) mice, whereas it was easily detectable in both the (ϩ/Ϫ) and (ϩ/ϩ) mice (Fig. 7) . Feeding the mice a diet containing 1% cholesterol and 0.5% cholate caused a 75% reduction in the intestinal expression of NPC1L1 in both (ϩ/ϩ) and (ϩ/Ϫ) mice compared with chow-fed mice of the same genotype (Fig. 7) . The reduced intestinal uptake of sterols in the chow-fed NPC1L1 (Ϫ/Ϫ) mice resulted in a 3.5-fold increase in the expression of mRNA for the cholesterol synthetic enzyme HMG-CoA synthase relative to expression in the (ϩ/ϩ) and (ϩ/Ϫ) mice (Fig. 7) . Intestinal cholesterol synthesis from orally administered [
14 C]mevalonate was found to be increased 3.9-fold in chow-fed NPC1L1 null (Ϫ/Ϫ) mice relative to wild type (ϩ/ϩ) mice (8.3 ϫ 10 6 and 2.1 ϫ 10 6 dpm, respectively, p Ͻ 0.05), consistent with the observed increase in HMG-CoA synthase. Intestinal HMG-CoA synthase mRNA expression levels remained elevated in the (Ϫ/Ϫ) mice when they were fed the cholesterol-containing diet, whereas expression decreased 60 and 80% with cholesterol feeding in the (ϩ/Ϫ) and (ϩ/ϩ) mice, respectively, compared with chow-fed mice of the same genotype (Fig. 7) . The intestinal mRNA expression of ABCA1 was reduced by 75% in the chow-fed NPC1L1 (Ϫ/Ϫ) mice relative to the (ϩ/ϩ) mice (Fig. 7) . Intestinal ABCA1 mRNA levels tended to increase with cholesterol feeding in the (ϩ/ϩ) and (ϩ/Ϫ) mice, whereas levels remained unchanged and reduced in the NPC1L1 null mice (Fig. 7) . Expression of ABCG5 was essentially the same for NPC1L1 (ϩ/ϩ), (ϩ/Ϫ), and (Ϫ/Ϫ) mice, and changes in the intestinal expression of ABCG5 mRNA with cholesterol feeding did not reach statistical significance for any of the groups (Fig. 7) . Similar results were obtained for intestinal expression levels of ABCG8 mRNA (data not shown).
DISCUSSION
NPC1L1 null (Ϫ/Ϫ) mice were found to be phenotypically normal, with no abnormalities in any parameters except intestinal sterol absorption. The focal and limited tissue and cellular distribution of NPC1L1 may be responsible for the lack of any detrimental effects in the NPC1L1 null mice. In the present study specific cellular localization was revealed by the LacZNeo cassette expression in the jejunal enterocytes. Previously it was reported that NPC1L1 mRNA expression in the mouse was highest in the proximal intestine, with the only other tissue expression found in the stomach and gall bladder, which had less than 5% of the intestinal expression (5) . In situ hybridization and immunohistochemical results of this study demonstrated that NPC1L1 was also localized to the jejunal enterocyte (5) .
Intestinal cholesterol uptake and absorption was found to be significantly reduced in the NPC1L1 null mice. Cholesterol absorption was reduced by nearly 90% in the NPC1L1 mice, which is similar to the inhibition of cholesterol absorption found in ezetimibe-treated wild type and SR-B1 null mice (6) and rats (3) . The uptake of cholesterol into the enterocytes of the jejunum was substantially reduced in the NPC1L1 null mice, indicating that this protein plays an essential role in the uptake of cholesterol from the lumen of the intestine to the brush border membrane of the enterocyte. Ezetimibe-treated mice and rats also demonstrate a reduction the intestinal uptake of cholesterol into jejunal enterocytes (3, 6) . Triglyceride uptake by the intestine and its absorption was not altered in the NPC1L1 null mice. This finding is also similar to that with ezetimibe-treated animals, where fatty acid absorption from triglycerides or cholesteryl esters (3) or the triglyceride content of postprandial chylomicrons are not altered (10) . Overall, the profile of cholesterol absorption in the NPC1L1 null mice closely resembles the profile of an ezetimibe-treated animal.
Plasma cholesterol levels in chow-fed NPC1L1 null (Ϫ/Ϫ), (ϩ/Ϫ), and (ϩ/ϩ) mice were found to be similar when determined by GC or enzymatic analysis (Fig. 3 and 4) . It was previously determined that the reduced delivery of intestinal cholesterol to the liver resulted in a compensatory 3.8-fold 6 . Effect of cholesterol feeding on VLDL, LDL, and high density lipoprotein (HDL) cholesterol levels in NPC1L1 knockout mice. Plasma lipoprotein fractions were pooled from fast protein liquid chromatography-separated lipoproteins from NPC1L1 null (Ϫ/Ϫ) (black bars), heterozygous (ϩ/Ϫ) (hatched bars), and wild type (ϩ/ϩ) (white bars) mice fed a diet containing 1% cholesterol and 0.5% sodium cholate for 7 days. A group of cholesterol-fed (ϩ/ϩ) mice were treated with ezetimibe (EZE; 10 mg/kg/day) for 7 days (stripped bars). Pooled lipoprotein cholesterol levels were determined in VLDL (fractions [15] [16] [17] [18] [19] , LDL (fractions 20 -27), and high density lipoprotein (fractions 28 -35 from Fig. 5 ). Values are the mean Ϯ S.E., with n ϭ 4 -5/group; *, p Ͻ 0.05 compared with cholesterol-fed wild type mice (ϩ/ϩ) mice.
up-regulation of the mRNA encoding the cholesterol synthetic enzyme HMG-CoA synthase in the livers of chow-fed NPC1L1 (Ϫ/Ϫ) mice (5). The up-regulation of hepatic cholesterol synthesis resulted in unchanged plasma cholesterol levels in the (Ϫ/Ϫ) mice. Hepatic and whole body cholesterol synthesis is also up-regulated in animals and humans treated with ezetimibe due to the inhibition of dietary and biliary cholesterol absorption (4, 11) . These results form the basis for the coadministration of ezetimibe with the HMG-CoA reductase inhibitors, statins, which inhibit hepatic cholesterol synthesis. By inhibiting both major sources of cholesterol, synthesis and intestinal absorption, dramatic reductions in plasma cholesterol levels occur (11, 12) .
Phytosterols are poorly absorbed compared with cholesterol, and it is not known whether the two sterol classes are taken up by the same mechanism in the intestine. Plasma levels of the plant sterols campesterol and sitosterol were found to be nearly undetectable in the NPC1L1 null mice and reduced by greater than 90% compared with wild type mice. Plasma phytosterol levels were also significantly reduced by 37-50% in the heterozygous NPC1L1 mice. Labeled sitosterol absorption and uptake in the intestine of the NPC1L1 null mice was substantially reduced, very similar to the reductions observed in wild type mice treated with ezetimibe. Clinically, ezetimibe treatment for 2 weeks resulted in the reduction of plasma sitosterol and campesterol levels by 41 and 48%, respectively (4). Humans and mice do not have the ability to enzymatically synthesize phytosterols from cholesterol, so phytosterol levels are more dramatically reduced relative to cholesterol in ezetimibetreated patients and NPC1L1 null mice. These results indicate that NPC1L1 is important for the uptake of both cholesterol and structurally related phytosterols and that ezetimibe acts through the pathway that contains NPC1L1.
This conclusion is further supported by studies in sitosterolemic patients and animal models of phytosterol efflux. Sitosterolemia is caused by mutations in the ATP binding cassette proteins ABCG5 or ABCG8, which are responsible for phytosterol efflux in the intestine and hepatic clearance into bile (13) (14) (15) . The patients exhibit an enhanced absorption and reduced biliary excretion of phytosterols, with concomitant increases in plasma and tissue phytosterol concentrations. When patients with sitosterolemia were treated with ezetimibe for 8 weeks, a progressive reduction in plasma sitosterol (-21%) and campesterol (-24%) levels was observed (7), giving ezetimibe a primary indication for the treatment of sitosterolemia and indicating that the ABCG5/G8 transporter is not required for ezetimibe action. Furthermore, there are no significant alterations in intestinal and hepatic expression of ABCG5 and ABCG8 in NPC1L1 (Ϫ/Ϫ) or (ϩ/Ϫ) mice (5). These results indicate that ezetimibe does not reduce plasma phytosterols or cholesterol through an interaction with ABCG5 or ABCG8 or by increasing their expression and suggest that ezetimibe acts through NPC1L1 to prevent the intestinal influx of both cholesterol and structurally related phytosterols.
Ezetimibe has been previously found to render cholesterolfed wild type, SR-B1 null, and apoE null mice resistant to hypercholesterolemia, primarily through reductions in chylomicron, VLDL and LDL cholesterol levels (6, 16) . To determine whether the NPC1L1 null mice were resistant to diet-induced hypercholesterolemia, groups of NPC1L1 (ϩ/ϩ), (ϩ/Ϫ), and (Ϫ/Ϫ) mice were fed a diet containing 1% cholesterol and 0.5% sodium cholate. Both (ϩ/Ϫ) and (Ϫ/Ϫ) mice were completely resistant to this severely hypercholesterolemic diet, with no change in their plasma total cholesterol levels or lipoproteincholesterol profiles. The plasma lipoprotein profile of cholesterol-fed, ezetimibe-treated (ϩ/ϩ) mice did not change and was similar to the cholesterol-fed (Ϫ/Ϫ) mice. The ezetimibe treatment and NPC1L1 deficiency yield the same phenotype with respect to resistance to diet-induced hypercholesterolemia.
Acyl-CoA:cholesterol acyltransferase (ACAT) 2 has been reported to play a role in intestinal cholesterol absorption in mice (17) . ACAT2-deficient mice fed a chow diet have normal cholesterol absorption but are resistant to hypercholesterolemia when fed diets containing cholesterol and cholic acid (17) . Cholesterol esterification by ACAT2 in the endoplasmic reticulum of enterocytes is thought to be responsible for the formation of the cholesteryl esters in the core of chylomicrons. Based on our observations, we hypothesize that ACAT2 is downstream from NPC1L1 in the cholesterol absorption pathway and only becomes rate-limiting for chylomicron assembly when the flux of cholesterol through the enterocyte is high, as occurs with high levels of dietary cholesterol. Heterozygous ACAT2-deficient mice are only partially resistant to diet-induced hypercholesterolemia (17) , whereas the NPC1L1 heterozygous mice were completely resistant. Therefore, the expression level of NPC1L1 appears to be the primary regulator of intestinal cholesterol absorption under both high and low dietary cholesterol conditions.
Cholesterol feeding animals will cause an accumulation of cholesterol in their livers, and hepatic cholesterol levels can be used as a surrogate marker for cholesterol absorption (2) . Hepatic cholesterol content was only slightly increased in the cholesterol-fed NPC1L1 null (Ϫ/Ϫ) mice relative to chow-fed mice and was similar to the level observed in ezetimibe-treated wild type mice. The level of hepatic cholesterol accumulation in NPC1L1 (ϩ/Ϫ) mice indicated that cholesterol absorption was not completely inhibited in the heterozygotes, suggesting a gene dosage effect. These results are consistent with the results directly measuring cholesterol absorption and with those previously reported using the dual fecal isotope method in mice fed a chow or cholate-containing diet (5) . Taken together, the observations are consistent with NPC1L1 deficiency or inhibition by ezetimibe causing a significant reduction in intestinal cholesterol absorption (1-6, 8, 10 -12) . Cholesterol levels in gall bladder bile increased in the cholesterol-fed wild type mice and were significantly lower in the NPC1L1 (Ϫ/Ϫ), (ϩ/Ϫ), and ezetimibe-treated wild type mice. These results are consistent with other studies showing an inhibition in the rise in biliary cholesterol levels in cholesterol-fed mice treated with an ezetimibe-analog cholesterol absorption inhibitor (18) .
Intestinal NPC1L1 mRNA expression was found to be downregulated in cholesterol/cholate-fed wild type and NPC1L1 heterozygous mice. NPC1L1 contains a sterol-sensing domain like many other proteins involved in cholesterol metabolism (19) . Sterol-regulated elements and a Ying Yang-1 binding site are present in the promoter region of NPC1L1, both of which have been implicated in sterol regulation of mRNA expression (19, 20) . The down-regulation of intestinal NPC1L1 in the presence of the high cholesterol/cholate diet is consistent with the sterol regulatory element-binding protein (SREBP)/SREBP cleavageactivating protein complex staying intact, preventing the bHLH-Zip domain binding to the sterol-regulated element in the NPC1L1 promoter (20) . Further exploration of the regulation of NPC1L1 by sterols will define whether its expression is similar to other genes regulated by sterol regulatory elementbinding proteins (20) .
Because cholesterol synthesis and cellular uptake is tightly regulated, blocking intestinal cholesterol uptake by NPC1L1 deficiency might be expected to affect the intestinal expression of genes involved in sterol metabolism. Intestinal HMG-CoA synthase mRNA was increased in both chow and cholesterol/ cholate-fed NPC1L1 null mice, in contrast to NPC1L1 (ϩ/Ϫ) and (ϩ/ϩ) mice, where HMG-CoA synthase was down-regulated with cholesterol/cholate feeding. Without cholesterol entering the jejunal enterocytes via the NPC1L1 pathway, cholesterol synthesis was up-regulated to maintain normal cellular levels and chylomicron production for triglyceride absorption. The ATP binding cassette transporter ABCA1 plays a role in the cellular efflux of phospholipids and cholesterol to apoA1 (21) , and expression of ABCA1 is up-regulated through LXR in response to increased cellular cholesterol levels (22) . Although normal regulation of ABCA1 mRNA occurred in NPC1L1 (ϩ/ϩ) and (ϩ/Ϫ) mice in response to cholesterol/ cholate feeding, intestinal ABCA1 mRNA expression was substantially reduced in the NPC1L1 null mice fed chow or cholesterol/cholate-containing diets. The regulatory cholesterol levels in NPC1L1 (Ϫ/Ϫ) jejunal enterocytes must be reduced relative to those of wild type mice and below the level required to induce ABCA1 for cholesterol efflux. The ATP binding cassette co-transporters ABCG5 and ABCG8 are thought to efflux enterocyte sterols back into the lumen of the intestine (13) (14) (15) . ABCG5 and ABCG8 mRNA levels are also increased via LXR by increased cellular sterol levels, but no change in the expression of either of these two sterol co-transporters was observed in the jejunum of NPC1L1 null mice (5) . The difference in regulation between ABCA1 and ABCG5/8 gene expression in the NPC1L1 (Ϫ/Ϫ) mice suggests that they are differentially sensitive to cellular cholesterol levels. These results are consistent with a previous report of a down-regulation of jejunal ABCA1, increased HMG-CoA synthase, and no change in ABCG5 or ABCG8 mRNA levels in chow-fed wild type 129/Sv mice treated with the ezetimibe analog SCH 58053 (18) . Taken together, these results imply that in both ezetimibe-treated and NPC1L1 null mice, sterol uptake into jejunal enterocytes is substantially reduced, and enterocyte cholesterol metabolism is altered to respond to decreased cellular cholesterol.
Overall, these results indicate that NPC1L1 plays a key role in intestinal and whole body cholesterol homeostasis and is required for intestinal uptake of cholesterol and phytosterols. In addition, NPC1L1 may be a useful drug target for treating individuals with hypercholesterolemia and sitosterolemia.
